ChordArt TMVr System
Primary (Degenerative) Mitral Regurgitation
ClinicalActive
Key Facts
About CoreMedic
CoreMedic is a private, clinical-stage medical device company pioneering a minimally invasive treatment for mitral valve disease. Its flagship product, the ChordArt TMVr system, aims to replicate surgical chordal replacement via a catheter, positioning it as a potential first-line therapy for patients with severe primary mitral regurgitation. The company has progressed through initial human trials with positive five-year data and is led by a management team with deep experience in cardiovascular device development and commercialization. CoreMedic is currently pre-revenue and working towards making its system available to patients.
View full company profile